What does Matrixyl do?

Matrixyl is a cosmetic trade name for palmitoyl pentapeptide-4, also called Pal-KTTKS. The supplied evidence frames it as a topical collagen-fragment peptide studied for fine lines, firmness, skin texture, and collagen-related skin support rather than as a drug or injectable treatment.

How does Matrixyl work?

The source describes KTTKS as a short type I collagen fragment that can act as a matrikine signal. In that model, fibroblasts respond to the fragment by increasing extracellular-matrix support proteins. The palmitoyl group is included to make the peptide more compatible with the skin barrier for topical delivery.

Is Matrixyl FDA approved?

No. The supplied source lists Matrixyl as not FDA approved and describes its current role as cosmetic use rather than an approved drug indication.

What side effects are reported for Matrixyl?

The supplied source characterizes Matrixyl as generally well tolerated. Reported issues include rare redness and rare itching, with minimal systemic absorption noted for topical use.

What dose information is available for Matrixyl?

The source reports limited community dosing information. Research-oriented entries mention topical serums or creams, 3-8% in formulations, and an 8-12 week window for visible results; a cited study narrative also mentions 3 ppm Pal-KTTKS in a moisturizer over 12 weeks.

Skin & Hair Research - early research

Matrixyl

Also known as: Palmitoyl Pentapeptide-4, Pal-KTTKS

At a glance

PeptiGuide dataset · reviewed Aug 2026

What it is

Topical palmitoyl pentapeptide-4 studied for collagen-related skin aging markers

Status

Research

Evidence level: early research

Typical dose

Limited community data; research entries report 3-8% topical formulations

Topical skin application in serums or creams

Researched for

Collagen production, anti-aging, skin firmness

Trial progress

PrePreclinical
IPhase I
IIPhase II
IIIPhase III
IVPhase IV
FDAFDA approved

Preclinical - Limited evidence and no established human dosing

Use the tools

In plain language

Matrixyl is palmitoyl pentapeptide-4, also known as Pal-KTTKS, and is used as a topical cosmetic ingredient. The supplied evidence focuses on collagen production, skin firmness, texture, and fine lines. It is not FDA approved, and the evidence status is best treated as limited research rather than drug-level proof. Dosing evidence is mainly topical formulation context, with limited community data.

How it's thought to work

Matrixyl is described as Pal-KTTKS, a palmitoylated form of a five-amino-acid collagen fragment. The KTTKS segment is presented as a matrikine-style signal associated with extracellular-matrix turnover, while the palmitoyl tail is used to improve compatibility with topical delivery through the outer skin barrier. The supplied evidence distinguishes this collagen-signaling model from muscle-targeting wrinkle approaches.

What the research shows

Where the research stands

The source highlights a 12-week double-blind, placebo-controlled split-face study in 93 women aged 35 to 55 that compared a Pal-KTTKS moisturizer with the same base moisturizer. It reports improvements in fine lines and wrinkles on the -treated side with good tolerability. Laboratory evidence cited in the source points toward increased collagen I, collagen IV, and fibronectin synthesis. The source also cautions that large percentage claims often trace back to manufacturer or formulation data, so exact promotional figures should not be treated as settled clinical outcomes.

What it shows

✓ Early research

Limited evidence and no established human dosing

△ Limitations

Early research findings may not translate directly to human outcomes.

Bottom line: Cosmetic use; extensively studied Not FDA approved

Typical dosing

CommunityCommunity dataset

Limited community data available

See research protocols

Range: See research dosing

Community dosing evidence is limited in the supplied source and should be treated as non-clinical user-reported context. · Topical (serums, creams)

Research dosing

Early researchEarly research - limited data

Doses observed in studies

3-8% in formulations

Research literature

3 ppm Pal-KTTKS

Robinson 2005 split-face trial

Early research findings may not translate directly to human outcomes.

Duration: 8-12 weeks for visible results, ongoing use
Administration: Topical (serums, creams)

Timing & administration

Best time to take

Morning or as directed

Follow recommended protocol

Food recommendation

With or without food

Why this timing?

The supplied source does not identify a precise timing requirement; it emphasizes that regular use is more relevant than a specific time of day.

Possible side effects

Not everyone experiences these. Individual responses vary with dose, duration, and personal factors.

Generally well tolerated
Redness
Itching
Minimal systemic absorption

Not everyone experiences side effects, and severity can vary by context, purity, route, and individual health factors.

Sources

PubMed ClinicalTrials.gov FDA.gov

Frequently asked questions

Sequence

palmitoyl-Lys-Thr-Thr-Lys-Ser-OH (Pal-KTTKS)

One open dataset

Every fact on this page - doses, side effects, references - comes from the same PeptiGuide dataset that powers the Tracker, Compare, and the Lab.

Browse the dataset

Save to my research list Get updates on Matrixyl

Educational resource, not medical advice. Talk to your clinician before acting on anything here.

Community discussion

Comments are moderated before they appear. Keep it evidence-focused.

Matrixyl

In plain languageIn plain language

How it's thought to workHow it's thought to work

What the research showsWhat the research shows

Typical dosing

Research dosing

Timing & administrationTiming & administration

Possible side effectsPossible side effects

SourcesSources

Frequently asked questionsFrequently asked questions